Nav: Home

Researchers reveal novel therapeutic strategy for ALS

April 09, 2019

In a study published online in Brain on April 1, researchers from Dr. XU Jin's lab at the Institute of Neuroscience of the Chinese Academy of Sciences and their collaborators revealed a new cellular mechanism for amyotrophic lateral sclerosis (ALS), suggested a novel therapeutic strategy targeting the RNA degradation pathway, and identified an asthma drug as a potential medication for ALS.

ALS is the most common motor neuron disease and one of the most devastating neurodegenerative diseases caused by progressive motor neuron degeneration. There is no cure for the disease and current treatment options are very limited. Thus, the disease is characterized by fast progression and high lethality.

Recent genetic advances have identified a group of new genes whose mutations contribute to the development of ALS. Among these genes, C9orf72 is the most common genetic cause of familial ALS, and even contributes to sporadic ALS.

Unlike commonly seen point mutations and deletions, (GGGGCC)n hexa-nucleotide repeats expansion (HRE) in a non-coding region of C9orf72 is the culprit. Intriguingly, these repeats could generate RNA and protein products and affect RNA metabolism as some other ALS-causing mutant proteins do, although the underlying mechanisms remain to be fully understood.

In this study, by coupling unbiased bioinformatic analysis of various transcriptome studies with validation experiments in multiple C9orf72 cellular and animal models, Dr. XU's team unveiled the inhibition of the nonsense-mediated mRNA decay (NMD) pathway as a conserved consequence of the C9orf72 HRE.

NMD is a type of RNA surveillance machinery vital for the removal of defective or harmful RNA generated from faulty transcription, alternative splicing or viral infection. Key protein components of NMD are found in cytoplasmic structures called processing bodies.

Interestingly, researchers found that HRE-derived neurotoxic dipeptide repeats (DPRs) could inhibit the NMD pathway by suppressing processing-body formation while promoting stress granule formation.

To test whether the NMD pathway could be a potential therapeutic target for ALS, they first genetically reactivated the NMD pathway and found that core NMD genes, such as UPF1, could effectively protect against C9orf72 DPRs neurotoxicity. Next, after evaluating several potential NMD-activating compounds, they identified Tranilast as the most promising NMD-activating drug and found that it could rescue cells and fruit flies from C9orf72 DPR-induced neurotoxicity.

Given that blood-brain barrier-permeable Tranilast has been clinically used to treat asthma with a great safety record since the 1980s, this study will prompt future pre-clinical and clinical investigations to test the therapeutic potential of Tranilast and other NMD-activating compounds in ALS patients with defective RNA metabolism.
-end-
The patent related to this discovery is pending.

Chinese Academy of Sciences Headquarters

Related Amyotrophic Lateral Sclerosis Articles:

Researchers perform thousands of mutations to understand amyotrophic lateral sclerosis
Researchers from IBEC and CRG in Barcelona use a technique called high-throughput mutagenesis to study Amyotrophic Lateral Sclerosis (ALS), with unexpected results.
How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.
Putting the brakes on lateral root development
Biologists have discovered a cellular transporter that links two of the most powerful hormones in plant development -- auxin and cytokinin -- and shows how they regulate root initiation and progression.
Lateral extra-articular tenodesis reduces hamstring autograft
The addition of lateral extra-articular tenodesis to a hamstring autograft in knee surgery in young active patients significantly reduces graft failure and persistent anterolateral rotatory laxity at two years post operatively.
Obesity worsens disability in multiple sclerosis
Obesity is an aggravating factor in relapsing-remitting multiple sclerosis, the most common form of the disease.
A new culprit for multiple sclerosis relapses
A molecule that helps blood clot may also play a role in multiple sclerosis relapses, researchers report in the May 6, 2019 issue of PNAS.
Two independent mechanisms are involved in tuberous sclerosis
The development of the rare condition called tuberous sclerosis involves mTORC1-dependent and -independent mechanisms.
New therapy for amyotrophic lateral sclerosis successfully tested on mice
A team from Université Laval and the CERVO Brain Research Centre has demonstrated the efficacy in mice of a new therapy that addresses the main manifestation of amyotrophic lateral sclerosis (ALS).
Multiple sclerosis: Perilous ruptures
The permanent neurological deficits of multiple sclerosis patients largely depend on the extent of degeneration of long nerve fibers.
Multiple sclerosis -- Helping cells to help themselves
Diseases such as multiple sclerosis are characterized by damage to the 'myelin sheath', a protective covering wrapped around nerve cells akin to insulation around an electrical wire.
More Amyotrophic Lateral Sclerosis News and Amyotrophic Lateral Sclerosis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.